BGM Group Ltd. BGM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-01-12
Chart by TradingView
5/9
Piotroski F — financial health
7.83
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $25.1M | $46.5M | $64.9M | $57.1M | $50.0M |
| Gross profit | $4.1M | $1.8M | $6.2M | $5.6M | $7.5M |
| Operating income | -$563,771 | -$2.6M | $2.1M | $2.4M | $4.8M |
| Net income | -$1.4M | -$7.8M | $1.1M | $3.2M | $5.1M |
| Operating cash flow | $544,238 | $312,209 | $12.7M | $345,034 | $5.1M |
| Free cash flow | $304,105 | $132,450 | $10.6M | -$1.1M | $4.6M |
| Total assets | $53.0M | $51.3M | $64.5M | $75.4M | $48.1M |
| Total liabilities | $8.9M | $6.9M | $9.6M | $18.7M | $19.3M |
| Shareholders' equity | $42.7M | $44.4M | $55.0M | $56.7M | $28.8M |
| Ratios | |||||
| Gross margin | 16.4% | 3.8% | 9.6% | 9.9% | 15.1% |
| Operating margin | -2.2% | -5.6% | 3.2% | 4.2% | 9.6% |
| Net margin | -5.7% | -16.7% | 1.7% | 5.5% | 10.1% |
| FCF margin | 1.2% | 0.3% | 16.4% | -2.0% | 9.2% |
| Return on assets | -2.7% | -15.2% | 1.7% | 4.2% | 10.5% |
| Return on equity | -3.4% | -17.5% | 2.0% | 5.6% | 17.6% |
| Current ratio | 3.39 | 5.18 | 3.27 | 2.22 | 2.04 |
| Revenue growth | -46.0% | -28.3% | 13.6% | 14.1% | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.83 (safe)
- Working capital / assets 0.396
- Retained earnings / assets 0.082
- EBIT / assets -0.011
- Equity / liabilities 4.797
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001779578 · as of 2024-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.